On May 25, 2023 NKGen Biotech Inc. ("NKGen"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, reported an upcoming poster presentation by its parent company, NKMax Co., Ltd., on preclinical and clinical data from a Phase I/IIa study of SNK01 in combination with cytotoxic chemotherapy in non-small cell lung cancer, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held at the McCormick Place Convention Center in Chicago, Illinois from June 2-6, 2023 (Press release, NKMax America, MAY 25, 2023, View Source [SID1234632066]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study

Authors: Myeong Geun Choi, Gun Woo Son, Dae-Hyun Ko, Wonjun Ji, Jin Kyung Rho, Jae Cheol Lee, Yong Man Kim, Jae Seob Jung, Paul Y. Song, Byeong Gon Yoon, Jong-min Jo, Mi Young Choi, Chang-Min Choi

Abstract Number: 9057

Session Type: Poster

Session Title: Lung Cancer – Non-Small Cell Metastatic

Poster Board Number: 45

Session Time: Sunday, June 4, 2023; 8:00 a.m. – 11:00 am CT

Location: Hall A

Full abstracts will be released at 5:00 pm ET on Thursday, May 25, 2023. Visit the 2023 ASCO (Free ASCO Whitepaper) Annual Meeting website at View Source for more information.